The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro

Cardiovascular Research

Volumn 101, Issue 3, 2014, Pages 513-521

  Maguire, Janet J ^a   Jones, Katie L ^a   Kuc, Rhoda E ^a   Clarke, Murray C H ^a   Bennett, Martin R ^a   Davenport, Anthony P ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

CCR5; Human coronary artery; Maraviroc; Saphenous vein graft disease; Vasoconstriction

Indexed keywords

CCR5; HUMAN CORONARY ARTERY; MARAVIROC; SAPHENOUS VEIN GRAFT DISEASE; VASOCONSTRICTION;

ATHEROSCLEROSIS; CELLS, CULTURED; CHEMOKINES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERPLASIA; MUSCLE, SMOOTH, VASCULAR; ORGAN CULTURE TECHNIQUES; RECEPTORS, CCR5; SAPHENOUS VEIN; TUNICA INTIMA; VASOCONSTRICTION;

EID: 84894543366     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt333     Document Type: Article

References (58)

1. Combadiere C, Ahuja SK, Tiffany HL, Murphy PM. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1a, MIP-1b and RANTES. J Leukoc Biol 1996;60:147-152.
2. Raport CJ, Gosling J, Schweickart VL, Gray PW, CharoIF. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1a and MIP-1b. J Biol Chem 1996;271:17161-17166.
3. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996;35: 3362-3367.
4. Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 2008;48:171-197.
5. Deng H, Liu R, Ellmeier W, Choe S, Unutmatz D, Burkhart M et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
6. Dragic T, Litwin V, AllawayGP, Martin SR, Huang Y, Nagashima KA et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381: 667-673.
7. Liu R, PaxtonWA, Choe S, Ceradini D, Martin SR, Horuk R et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
8. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber C-L et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 1996;382:722-725.
9. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-4732.
10. Boccara F, Cohen A, Di Angelantonio E, Meuleman C, Ederhy S, DufaitreGet al. Coronary artery bypass graft in HIV-infected patients: a multicenter case control study. Curr HIV Res 2008;6:59-64.
11. Martinez E, Larrousse M, Gatell JM. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis 2009;22:28-34.
12. Dubé MP, Lipschultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD and for working group 3. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 2008;118:e36-e40.
13. Jang Y, Chae JS, Hyun YJ, Koh SJ, Kim JY, Ko MJ et al. The RANTES-403G.A promoter polymorphism in Korean men: association with serum RANTES and coronary artery disease. Clin Sci (Lond) 2007;113:349-356.
14. DiPalma S, Frohlich JJ, Hill JS. RANTES levels predict angiographic coronary artery disease but not mortality in an angiography population. Arterioscler Thromb Vasc Biol 2008;28:e32-e149, P489.
15. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK.Chemokines in cardiovascular risk prediction. Thromb Haemost 2007;97:748-754.
16. Pai JK, Kraft P, Cannuscio CC, Manson JE, Rexode KM, AlbertCMet al. Polymorphisms in the CC-chemokine receptor-2 (CCR2) and-5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 2006;186:132-139.
17. Mettimano M, Speccia ML, Ianni A, Arzani D, Ricciardi G, Savi L et al. CCR5 and CCR2 gene polymorphisms in hypertensive patients. Br J Biomed Sci 2003;60:19-21.
18. Zhang M, Ardlie K, Wacholder S, Welch R, Chanock S, O'Brien TR. Genetic variations in CC chemokine receptors and hypertension. Am J Hypertens 2006;19:67-72.
19. Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA et al. Multicenter AIDS Cohort Study. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005;19:953-960.
20. Palacios R, Santos J, Garc?́a A, Castells E, González M, Ruiz J et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients.Aprospective study in a cohort of naive patients. HIV Med 2006;7:10-15.
21. Almodovar S, Knight R, Allshouse AA, Roemer S, Lozupone C, McDonaldDet al.Human Immunodeficiency Virus nef signature sequences are associated with pulmonary hypertension. AIDS Res Hum Retroviruses 2012;28:607-618.
22. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez- BarradasMCet al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011;183:388-395.
23. Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):5-18.
24. Maguire JJ. Endothelin-converting enzyme activity in vascular smooth muscle preparations in vitro. Methods Mol Biol 2002;206:165-177.
25. Stupple PA, Batchelor DV, Corless M, Dorr PK, Ellis D, Fenwick DR et al. An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4, 5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl] propyl}acetamide (PF-232798). J Med Chem2011;54:67-77.
26. Soyombo AA, Angelini GD, Bryan AJ, Jasani B, Newby AC. Intimal proliferation in an organ culture of human saphenous vein. Am J Pathol 1990;137:1401-1410.
27. Porter KE, Varty K, Jones L, Bell PR, London NJ. Human saphenous vein organ culture: a useful model of intimal hyperplasia? Eur J Vasc Endovasc Surg 1996;11:48-58.
28. Cornelissen J. Human Coronary Artery Bypass Graft Occlusion. Bristol, UK: University of the West of England. 2005.
29. Lu Y, Nerurkar VR, Dashwood W-M, Woodward CL, Ablan S, ShikumaCMet al. Genotype and allele frequency of a 32-base pair deletion mutation in theCCR5gene in various ethnic groups: Absence of mutation among Asians and pacific islanders. Int J Infect Dis 1999;3:186-191.
30. Davenport AP, Kuc RE. Cellular localization of receptors using antibodies visualized by light and dual labeling confocal microscopy. Methods Mol Biol 2012;897:239-260.
31. Maguire JJ, Kuc RE, Davenport AP. Radioligand binding assays and their analysis. Methods Mol Biol 2012;897:31-77.
32. Pierson RN III, Barr ML, McCullough KP, Egan T, Garrity E, JessupMet al. Thoracic organ transplantation. Am J Transplant 2004;4:93-105.
33. Maguire JJ, Kuc RE, Rous BA, Davenport AP. Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments. Br J Pharmacol 1996;118:335-342.
34. Katugampola SD, Davenport AP. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol 2001;134:1385-1392.
35. Hayes IM, Jordan NJ, Towers S, Smith G, Paterson JR, Earnshaw JJ et al. Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol 1998;18:397-403.
36. Mieno S, Boodhwani M, Ramlawi B, Li J, Bianchi C, Laham RJ et al.Humancoronary microvascular effects of cardioplegia-induced stromal-derived factor-1alpha. Ann Thorac Surg 2006;82:657-663.
37. Eugenin EA, Morgello S, Klotman ME, Mosoian A, Lento PA, Berman JW et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 2008;172:1100-1111.
38. Schecter AD, Berman AB, Yi L, Mosoian A, McManus CM, BermanJWet al. HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA 2001;98: 10142-10147.
39. Schecter AD, Calderon TM, Berman AB, McManus CM, Fallon JT, Rossikhina M et al. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000;275: 5466-5471.
40. Afzal AR, Kiechl S, Daryani YP, Weerasinghe A, Zhang Y, Reindl M et al. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke 2008;39: 1972-1978.
41. Kraaijeveld AO, de Jager SCA, de Jager WJ, Prakken BJ, McColl SR, Haspels I et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007;116:1931-1941.
42. Gurbel PA, Kreutz RP, Bliden KP, DiChiara J, Tantry US. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J 2008;155:56-61.
43. Tatara Y, Ohishi M, Yamamoto K, Shiota A, Hayashi N, Iwamoto Y et al. Macrophage inflammatory protein-1beta induced cell adhesion with increased intracellular reactive oxygen species. J Mol Cell Cardiol 2009;47:104-111.
44. Castellheim A, Hoel TN, Videm V, Fosse E, Pharo A, Svennevig JL et al. Biomarker profile in off-pump and on-pump coronary artery bypass grafting surgery in low-risk patients. Ann Thorac Surg 2008;85:1994-2002.
45. Roubos N, Rosenfeldt FL, Richards SM, Conyers RAJ, Davis BB. Improved preservation of saphenous vein grafts by the use of glyceryl trinitrate-verapamil solution during harvesting. Circulation 1995;92:II31-II36.
46. Victor MF, Kimbiris D, Iskandrian AS, Mintz GS, Bemis CE, Procacci PM et al. Spasm of a saphenous vein bypass graft. A possible mechanism for occlusion of the venous graft. Chest 1981;80:413-415.
47. Rottman JB, Ganley KP, Williams K, Wu L, Mackay CR, Ringler DJ. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am J Pathol 1997;151:1341-1351.
48. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004;84:767-801.
49. Bursill CA, Channon KM, Greaves DR. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol 2004;15: 145-149.
50. Karshovska E, Schober A. Mechanisms of arterial remodeling and neointima formation: an updated view on the chemokine system. Drug Discov Today Dis Mech 2008;5: e293-e298.
51. Bacon CR, Cary NR, Davenport AP. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res 1996;79:794-801.
52. Maguire JJ, Davenport AP. Endothelin receptor expression and pharmacology in human saphenous vein graft. Br J Pharmacol 1999;126:443-450.
53. Jabs A, Okamoto E, Vinten-Johansen J, Bauriedel G, Wilcox JN. Sequential patterns of chemokine-and chemokine receptor-synthesis following vessel wall injury in porcine coronary arteries. Atherosclerosis 2007;192:75-84.
54. LukacsNW, Kunkel SL, Allen R, Evanoff HL, Shaklee CL, Sherman JS et al. Stimulus and cell-specific expression of C-X-C and C-C chemokines by pulmonary stromal cell populations. Am J Physiol 1995;268:L856-L861.
55. Poon M, Hsu WC, Bogdanov VY, Taubman MB. Secretion of monocyte chemotactic activity by cultured rat aortic smooth muscle cells in response to PDGF is due predominantly to the induction of JE/MCP-1. Am J Pathol 1996;49:307-317.
56. Lin YL, MettlingC, Portalès P, Rouzier R, Clot J, Reynes J et al. The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5. AIDS 2008;22:430-432.
57. Stark VK, Hoch JR, WarnerTF, Hullett DA. Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia. Arterioscler Thromb Vasc Biol 1997;17:1614-1621.
58. Pyo RT, Sui J, Dhume A, Palomeque J, Blaxall BC, Diaz G et al. CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol 2006;41:834-844.